Chronic Otitis Media (COM) Epidemiology Forecast Report Coverage
Expert Market Research's “Chronic Otitis Media (COM) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of chronic otitis media (COM). It projects the future incidence and prevalence rates of chronic otitis media (COM) cases across various populations. The study covers age, gender, and type as major determinants of the chronic otitis media (COM) population. The report highlights patterns in the prevalence of chronic otitis media (COM) over time and projects future trends based on multiple variables.The report provides a comprehensive overview of the disease, as well as historical and projected data on chronic otitis media (COM) epidemiology in the 8 major markets.
Regions Covered
- The United States
- Germany
- France
- Italy
- Spain
- The United Kingdom
- Japan
- India
Chronic Otitis Media (COM) Understanding: Disease Overview
Chronic otitis media (COM) is a long-standing inflammation of the middle ear characterized by tympanic membrane perforation, recurrent ear discharge, and progressive hearing loss. It often develops following unresolved acute otitis media or Eustachian tube dysfunction. The condition can be categorized into tubotympanic (safe) and atticoantral (unsafe/cholesteatomatous). Persistent infection by pathogens such as Pseudomonas aeruginosa or Staphylococcus aureus can lead to ossicular erosion and intracranial complications if untreated. The condition remains a major cause of preventable hearing impairment globally, particularly in low-income regions.Chronic Otitis Media (COM) Epidemiology Perspective
The chronic otitis media (COM) epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the chronic otitis media (COM) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for chronic otitis media (COM) and their trends. The chronic otitis media (COM) detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.- The global number of otitis media (all types) incident cases rose from 322.1 million in 1992 to 391.3 million in 2021, with a small increase in age-standardized incidence (~5,345 to ~5,529 per 100,000.
- Chronic suppurative otitis media (CSOM) is more common in children, though it may persist in adults, particularly in settings with weak healthcare access.
- Among children, incidence rose from ~256 million in 1990 to 297 million in 2021 (a ~16% increase), though age-standardized incidence remained relatively stable, likely reflecting population growth and demographic shifts.
- Non-White and Hispanic children are reportedly less likely to get evaluated by otolaryngologists or receive surgical interventions for otitis media, suggesting disparities in specialty access and treatment.
Country-wise Chronic Otitis Media (COM) Epidemiology Segment
The chronic otitis media (COM) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.In the United States, chronic otitis media, particularly chronic suppurative otitis media (CSOM), remains a significant otologic concern, predominantly affecting children. A national database analysis of approximately 679,906 CSOM patients reported a mean age of 8.1 years, with 81.1% aged 0-10 years and a slight male predominance (52.8%). The prevalence estimates indicate that COM affects around 1-2% of the U.S. population, translating to millions of cases annually. Despite widespread access to medical care, persistent disease continues among socioeconomically disadvantaged and rural populations.
Chronic Otitis Media (COM): Treatment Overview
The treatment of chronic otitis media aims to eradicate infection, close the tympanic membrane perforation, and restore hearing. Medical therapy includes aural toilet, topical or systemic antibiotics, and corticosteroids for inflammation control. Surgical management, tympanoplasty or mastoidectomy, is indicated in persistent or cholesteatomatous cases to remove disease and reconstruct middle-ear structures. Postoperative care emphasizes ear hygiene and follow-up to prevent recurrence. Hearing aids may assist in non-surgical candidates, while vaccination against pneumococcal and influenza infections helps reduce disease incidence and chronicity in vulnerable populations.Key Questions Answered
- What are the key findings of chronic otitis media (COM) epidemiology in the 8 major markets?
- What will be the total number of patients with chronic otitis media (COM) across the 8 major markets during the forecast period?
- What was the country-wise chronic otitis media (COM) epidemiology scenario in the 8 major markets in the historical period?
- Which country will have the highest number of cases of chronic otitis media (COM) during the forecast period of 2025-2034?
- Which key factors would influence the shift in the patient population of chronic otitis media chronic suppurative otitis media (COM) during the forecast period of 2025-2034?
- What are the currently available treatments for chronic otitis media (COM)?
- What are the disease risks, signs, symptoms, and unmet needs of chronic otitis media (COM)?
Scope of the Chronic Otitis Media (COM) Epidemiology Report
- The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of chronic otitis media (COM) based on several factors.
- Chronic Otitis Media (COM) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
- The chronic otitis media (COM) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.
This product will be delivered within 3-5 business days.

